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4  | DISCUSSION
In this study, we describe the management of sight‐threatening or‐
bitopathy in patients seen in a multidisciplinary thyroid‐eye outpa‐
tient clinic between 1995 and 2015.
Since 1995, 772 patients were seen for Graves’ orbitopathy 
(GO) in our outpatient clinic. Sight‐threatening GO occurred in 34 
patients, representing 4.4% of our population. Previously published 
data described sight‐threatening GO as a rare complication of GO 
occurring in 3%‐5% of patients.2 Our results are consistent with 
these data. Moreover, among the thirty‐one patients enrolled in this 
study, DON was the principal form of sight‐threatening GO before 
corneal ulcer (58% of patients with DON, 23% with corneal ulcer and 
19% with both clinical entities), and comparable to previous studies. 
The population characteristics were quite similar to previous studies 
but with some differences. The median age of sight‐threatening GO 
was 51 years old, which is younger than in other studies (median age 
56‐57 years old) except in the studies conducted by Wakelkamp et 
al or Jeon et al (median age 52 and 50 years old, respectively).3,7,8 
Women represent 77% of our population, which is comparable to 
other studies, but this figure is higher than in the study conducted 
by Currò et al where women represented 58% of the population.3,9 
Graves’ disease is the principal aetiology of thyroid pathology and 
radioiodine treatment was performed in 16% of our population. This 
is consistent with the EUGOGO study on DON carried out in 2007.10 
Interestingly, the number of patients seen for GO and for sight‐
threatening forms increased substantially between 1995 and 2015. 
But, this increase was not parallel. Indeed, between 1995 and 2000, 
sight‐threatening GO represented 1.4% of the population of our 
outpatient clinic compared to 2.0% between 2000 and 2005 5.0% 
between 2005 and 2010% and 5.5% between 2010 and 2015. To ex‐
plain these data, two hypotheses could be done. First, our data could 
suggest that GO has become increasingly severe in recent decades. 
Nevertheless, this hypothesis is not consistent with the PREGO 
study, which describes an increase in mild and inactive GO in Europe 
between 2000 and 2012.11 The second hypothesis is the fact that 
the appeal of our outpatient clinic has probably grown over the years, 
increasing the number of patients seen for sight‐threatening GO.
More common than corneal ulcer, DON poses a diagnostic chal‐
lenge. As described by Wiersinga and Kahaly,12 DON was diagnosed 
if optic disc swelling was present. In the absence of optic disc swelling, 
DON was diagnosed if two or more anomalies were present including 
decreased visual acuity, visual field defect, change in colour vision 
and/or radiological compression or stretching of the optic nerve. This 
definition requires thorough ophthalmological evaluation including 
visual acuity, visual field, funduscopy and colour vision evaluation. 
Patients with decreased visual acuity only cannot be considered for 
DON diagnosis. It is important for physicians to note this last point in 
order to avoid over‐diagnosis of DON. In our DON population, clini‐
cal features at presentation were as follows: reduced visual acuity in 
85% of cases, visual field defects in 80%, optic disc swelling in 42% 
and reduced colour vision in 100% (n = 7) of cases. Radiological signs 
were present in 60% of cases with DON. Concerning visual acuity 
and visual fields, our results are quite similar to previous studies,9,10,13 
but optic disc swelling is more frequent in our population than in the 
study conducted by Currò (17.5%). Radiological signs are present in 
60% of cases in our population compared to 88%‐100% of cases in 
the other studies. We cannot draw colour vision comparisons with 
other studies because of the lack of data (7 eyes out of 40).
DON represents both diagnostic and therapeutic challenges. 
Intra‐venous glucocorticoids and orbital decompression are the two 
principal strategies used to treat DON. Orbital radiotherapy is indi‐
cated as adjuvant treatment. Some case reports describe the use of 
new immunological treatment (as tocilizumab)14 but given the lack 
of larger scale studies, we cannot consider these treatments as con‐
ventional DON therapy. So far, just one randomized study compares 
medical versus surgical treatment for DON3 leading to EUGOGO 
recommendations for intra‐venous corticoids as first‐line treatment 
before surgery.15 In terms of intra‐venous glucocorticoid protocols, 
Guy JR et al treated DON with four pulses of 250 mg intra‐venous 
methylprednisolone on three consecutive days,16 Mourits et al ad‐
ministered four pulses of 500 mg on 2 days,9 Wakelkamp et al pro‐
pose daily pulses of 1 g on three consecutive days, repeating the 
same strategy the following week.3 No difference was observed 
between pulses of 500 mg or 1 g in the study carried out by Currò 
et al.13 In our study conducted between 1995 and 2015, various 
intra‐venous glucocorticoid protocols were used, ranging from one 
pulse of 500 mg intra‐venous methylprednisolone to 14 pulses of 
500 mg intra‐venous methylprednisolone (3 a week). However, no 
protocol exceeded a cumulative dose of 7 g of methylprednisolone. 
Moreover, management of DON required orbital decompression in 
82.5% of cases. Medical treatment (pulses of intra‐venous glucocor‐
ticoids with or without orbital radiotherapy) was performed alone in 
only 17.5% of cases. These data are very different from the litera‐
ture. Currò et al13 treated 42.5% of their cases of DON with medical 
treatment alone. In two previous studies, this rate of orbital decom‐
pression varied between 60% and 66%.3,9 Therefore, we cannot be 
sure that this difference is not related to a different classification of 
sight‐threatening GO in other studies that could lead to over‐diagno‐
sis of DON and thus explain the improved response to medical treat‐
ment. On the other hand, this difference could also be attributed to 
the various intra‐venous glucocorticoid protocols used in our study.
Corneal ulcer, the other entity of sight‐threatening GO, is less 
frequent than DON and sparse data are available about its man‐
agement.4‐6 In our study, corneal ulcer was very difficult to treat. 
Local treatment (eye drops and night‐occlusion) alone is mostly in‐
effective (3 patients out of 13 treated with local treatment alone). 
Ten patients required the use of different medical or surgical strat‐
egies (orbital decompression, punctal plug, amniotic membrane 
graft, tarsorrhaphy, botulinum toxin injection and eyelid surgery). 
The efficacy of one or other of these strategies is inconclusive 
because of the small number of studied patients. However, we are 
convinced that corneal ulcer requires close attention and treat‐
ment from the earliest symptoms.
Patient follow‐up is also critical in the management of sight‐
threatening orbitopathy. To establish whether treatment is effective, 
patients must be assessed 1 or 2 weeks after initial treatment. Currò 
et al13 show that initial medical treatment does not lead to poor 
prognosis on visual parameters even if is ineffective. In a cohort of 
moderate to severe GO, Bartalena shows that patients whose condi‐
tion deteriorated at 6 weeks have no chance to improve thereafter.
Indeed, the criteria for improvement are not very clear in the 
various studies. It is also important to monitor corticosteroid ther‐
apy for side effects. Nevertheless, the intra‐venous route appears 
safer than the oral route and cumulative doses under 8 g reduce 
serious side effects.17‐19 No severe adverse drug reactions were 
observed with glucocorticoids in our population. Long‐term follow‐
up produced good outcomes mostly in patients with DON or cor‐
neal ulcer. In a recent study, complete recovery of visual acuity was 
obtained using a combination of therapies (medical treatment, OD 
and radiotherapy) in 66.7% of DON patients.20 In addition to the 
use of different strategies, a multidisciplinary approach is required 
to ensure the more effective management of sight‐threatening GO.
Our study has some limitations. Firstly, it is a retrospective study. 
Some initial assessment or long‐term follow‐up data are unavailable. 
Various intra‐venous glucocorticoid protocols were used between 
1995 and 2015. Nevertheless, our study describes one of the most 
important cohorts of sight‐threatening GO (47 cases), including 15 
cases of corneal ulcer. Orbital decompression was performed in the 
majority of DON cases and several therapeutic strategies were nec‐
essary to treat corneal ulcer. However, with multidisciplinary thyroid‐
eye management, results are satisfactory for the majority of patients.
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